Scarica l'app Stockscreener
3.20
0.88%
-0.0285
Dopo l'orario di chiusura:
3.20
Precedente Chiudi:
$3.2285
Aprire:
$3.27
Volume 24 ore:
722
Relative Volume:
0.10
Capitalizzazione di mercato:
$10.19M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-4.19%
1M Prestazione:
-13.51%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$3.0215
$3.27
Intervallo di 1 settimana:
$2.8104
$3.3962
Portata 52W:
$2.8104
$6.60
Cosciens Biopharma Inc Stock (CSCI) Company Profile
Nome
Cosciens Biopharma Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta CSCI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| CSCI | 3.20 | 10.19M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Cosciens Biopharma Inc Borsa (CSCI) Ultime notizie
Canada Market's top losers: Draganfly Inc. with 13.78% drop, Digihost Technology Inc, 11.42% - Business Upturn
COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023) - Yahoo Finance
COSCIENS Biopharma: Q3 Earnings Snapshot - Houston Chronicle
COSCIENS Biopharma Advances Merger and Pipeline - TipRanks
Shimmick Announces New CEO - The Manila Times
COSCIENS Biopharma Inc. Reports Third Quarter 2024 - GlobeNewswire
COSCIENS Q3 Loss Widens to $5.8M, Discontinues Key Programs Amid Pipeline Shift | CSCI Stock News - StockTitan
CSCI stock touches 52-week low at $3.4 amid market fluctuations - Investing.com India
Hypoparathyroidism Market to Grow by USD 474.9 Million from 2024-2028, Driven by Thyroid Treatment Awareness Programs and AI-Powered Market InsightsTechnavio - PR Newswire
Cosciens Biopharma (TSX:CSCI) EPS without NRI : C$-4.32 (TTM As of Jun. 2024) - GuruFocus.com
AEterna Zentaris : March 10, 2015 Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2014 Financial and Operating Results on March 17, 2015 - Marketscreener.com
Yorvipath-finders? Septerna, others forge on in hypothyroidism - BioWorld Online
Cosciens Biopharma (FRA:ET8) Enterprise Value : €-13.18 Mil (As of Oct. 17, 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Cash From Discontinued Investi - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Profitability Rank : 5 (As of Jun. 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Shares Outstanding (EOP) : 3.06 Mil (As of Jun. 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Free Cash Flow : €-5.76 Mil (TTM As of Jun. 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Long-Term Debt & Capital Lease Obligation : €1.19 Mil (As of Jun. 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Inventory-to-Revenue : 1.40 (As of Jun. 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) 3-Year Revenue Growth Rate : -13.80% (As of Jun. 2024) - GuruFocus.com
Cosciens Biopharma (FRA:ET8) Cyclically Adjusted PS Ratio : 0.56 (As of Oct. 16, 2024) - GuruFocus.com
The Escalator: Syneos Health, The FDA, Pfizer and more - MM+M Online
COSCIENS Biopharma streamlines board with resignation By Investing.com - Investing.com Canada
COSCIENS Biopharma reshuffles board of directors By Investing.com - Investing.com South Africa
COSCIENS Biopharma streamlines board with resignation - Investing.com
COSCIENS Biopharma reshuffles board of directors - Investing.com India
Cosciens Biopharma director Carolyn Egbert resigns - TipRanks
COSCIENS Biopharma Restructures Board After Resignation - TipRanks
COSCIENS Biopharma Announces Change to Board of Directors - GlobeNewswire
AgEagle Aerial Systems Inc. Announces Closing of $6.5 Million Public Offering - The Manila Times
COSCIENS Biopharma names new board director By Investing.com - Investing.com South Africa
COSCIENS Biopharma names new board director - Investing.com
COSCIENS Biopharma Welcomes New Board Director - TipRanks
COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director - The Manila Times
Cintas (NASDAQ:CTAS) Reaches New 12-Month High at $209.59 - MarketBeat
Cintas Stock Hits All-Time High Amid Strong Results, Outlook Lift - MSN
Cintas stock soars to all-time high, hits $209.13 - Investing.com India
Cintas rises on raising annual profit, revenue forecasts - XM
Cintas’s shares rise on improved earnings guidance (NASDAQ:CTAS) - Seeking Alpha
Cintas Beats Q1 Earnings On Margin Strength, Boosts Outlook - Yahoo Finance UK
Cintas earnings beat by $0.10, revenue topped estimates - Investing.com Australia
Cintas (NASDAQ:CTAS) Releases FY25 Earnings Guidance - Defense World
Cintas stock gains 2% on Q1 earnings beat, raises full-year outlook - Investing.com Australia
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Buys 6,562 Shares of Cintas Co. (NASDAQ:CTAS) - Defense World
Colombia defeats ICSID case over internet domain name - Latin Lawyer
Scalar Gauge Management LLC Decreases Stock Position in Cintas Co. (NASDAQ:CTAS) - Defense World
Why Carpenter Tech (CRS) Stock is Surging Despite Boeing's (BA) Troubles - GuruFocus.com
COSCIENS Biopharma announces management changes, integration progress - Investing.com
Toronto Stocks Flat; Bitfarms Up on Settlement with Riot Platforms - Marketscreener.com
Cosciens Biopharma Shares Fall on ALS Treatment Research End, Cost Cutting - MarketWatch
Cosciens Biopharma provides update on development projects - TipRanks
Cosciens Biopharma Inc Azioni (CSCI) Dati Finanziari
Non sono disponibili dati finanziari per Cosciens Biopharma Inc (CSCI). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):